A share price of Travere Therapeutics Inc [TVTX] is currently trading at $21.75, down -0.50%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TVTX shares have gain 6.30% over the last week, with a monthly amount glided 13.99%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo upgraded its rating to Overweight on October 21, 2024, and elevated its price target to $27. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Guggenheim upgraded its rating to a Buy but stick to its price target of $25 on September 09, 2024. Guggenheim downgraded its rating to a Neutral. Citigroup upgraded its rating to Buy for this stock on December 05, 2023, and upped its price target to $10. In a note dated November 20, 2023, Citigroup initiated an Neutral rating and provided a target price of $7 on this stock.
Travere Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $5.12 and $22.13. Currently, Wall Street analysts expect the stock to reach $21.75 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $21.75 at the most recent close of the market.
Analyzing the TVTX fundamentals
Trailing Twelve Months sales for Travere Therapeutics Inc [NASDAQ:TVTX] were 203.45M which represents 69.56% growth. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -1.69%, Pretax Profit Margin comes in at -1.71%, and Net Profit Margin reading is -1.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -5.42 and Total Capital is -1.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-13.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.41 points at the first support level, and at 21.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.17, and for the 2nd resistance point, it is at 22.59.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Travere Therapeutics Inc [NASDAQ:TVTX] is 1.71. Also, the Quick Ratio is 1.68, while the Cash Ratio stands at 0.19. Considering the valuation of this stock, the price to sales ratio is 9.30.
Transactions by insiders
Recent insider trading involved ROY D BAYNES, Director, that happened on Feb 06 ’25 when 10000.0 shares were purchased. SENIOR VICE PRESIDENT, R&D, ROTE WILLIAM E. completed a deal on Feb 03 ’25 to sell 8951.0 shares. Meanwhile, SVP, GC & CORPORATE SECRETARY REED ELIZABETH E sold 8951.0 shares on Feb 03 ’25.
